CoChat

Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain

Open access
Osteen, Jeremiah D., Immani, Swapna, Tapley, Tim L., Indersmitten, Tim, Hurst, Nicole W., Healey, Tiffany, Aertgeerts, Kathleen, Negulescu, Paul A., Lechner, Sandra M. · 2025 · Pain and Therapy
Cited by 186

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

There is a high unmet need for safe and effective non-opioid medicines to treat moderate to severe pain without risk of addiction. Voltage-gated sodium channel 1.8 (Na V 1.8) is a genetically and pharmacologically validated pain target that is selectively expressed in peripheral pain-sensing neurons and not in the central nervous system (CNS). Suzetrigine (VX-548) is a potent and selective inhibitor of Na V 1.8, which has demonstrated clinical efficacy and safety in multiple acute pain studies. Our study was designed to characterize the mechanism of action of suzetrigine and assess both nonclinical and clinical data to test the hypothesis that selective Na V 1.8 inhibition translates into clinical efficacy and safety, including lack of addictive potential. Preclinical pharmacology and mechanism of action studies were performed in vitro using electrophysiology and radiolabeled binding methods in cells recombinantly expressing human Na V channels, human proteins, and primary human dorsal root ganglion (DRG) sensory neurons. Safety and addictive potential assessments included in vitro secondary pharmacology studies, nonclinical repeat-dose toxicity and dependence studies in rats and/or monkeys, and a systematic analysis of adverse event data generated from 2447 participants from phase 3 acute pain studies of suzetrigine. Suzetrigine is selective against all other Na V subtypes (≥ 31,000-fold) and 180 other molecular targets. Suzetrigine inhibits Na V 1.8 by binding to the protein’s second voltage sensing domain (VSD2) to stabilize the closed state of the channel. This novel allosteric mechanism results in tonic inhibition of Na V 1.8 and reduces pain signals in primary human DRG sensory neurons. Nonclinical and clinical safety assessments with suzetrigine demonstrate no adverse CNS, cardiovascular or behavioral effects and no evidence of addictive potential or dependence. The comprehensive pharmacology assessment presented here indicates that suzetrigine represents the first in a new class of non-opioid analgesics that are selective Na V 1.8 pain signal inhibitors acting in the peripheral nervous system to safely treat pain without addictive potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40122-024-00697-0

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 50

  1. Sinatra R. Causes and consequence of inadequate management of acute pain. Pain Med. 2010;11:1859–71. · DOI · Paper page
  2. Kent ML, Tighe PJ, Belfer I, et al. The ACTTION-APS-AAPM pain taxonomy (AAAPT) multidimensional approach to classifying acute pain conditions. J Pain. 2017;18:479–89. · DOI
  3. Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain. 2022;163(2):e328–32. · DOI · Paper page
  4. Fillingim RB, Bruehl S, Dworkin RH, et al. The ACTTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions. J Pain. 2014;5:241–9. · DOI · Paper page
  5. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90(4):532–45. · DOI · Paper page
  6. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1: CD007076.
  7. Russo M, Graham B, Santarelli DM. Gabapentin-friend or foe? Pain Pract. 2023;1:63–9. · DOI
  8. Maher AJ, Metcalfe SA, Parr S. Local anaesthetic toxicity. Foot (Edinb). 2008;18(4):192–7. · doi:10.1016/j.foot.2008.05.002
  9. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–71. · DOI · Paper page
  10. Machelska H, Celik MO. Advances in achieving opioid analgesia without side effects. Front Pharmacol. 2018;9:1388. · DOI · Paper page
  11. Tyndale RF, Sellers EM. Opioids: the painful public health reality. Clin Pharmacol Ther. 2018;103(6):924–35. · DOI
  12. Coussens NP, Sittampalam S, Jonson SG, et al. The opioid crisis and the future of addiction and pain therapeutics. J Pharmacol Exper Ther. 2019;371(2):396–408. · DOI · Paper page
  13. Kissin I. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg. 2010;110:780–9. · DOI · Paper page
  14. Eagles DA, Chow CY, King GF. Fifteen years of NaV1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy? Br J Pharm. 2022;179:3592–611. · DOI
  15. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci. 2009;10:283–94. · DOI · Paper page
  16. Krafte D, Bannon A. Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr Opin Pharmacol. 2008;8(1):50–6. · DOI
  17. Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The role of voltage-gated sodium channels in pain signaling. Physiol Rev. 2019;99(2):1079–151. · DOI · Paper page
  18. Catterall WA. Voltage-gated sodium channels at 60: structure, function and pathophysiology. J Physiol. 2012;590(11):2577–89. · DOI · Paper page
  19. Ahern CA, Payandeh J, Bosmans F, Chanda B. The hitchhiker’s guide to the voltage-gated sodium channel galaxy. J Gen Physiol. 2016;147:1–24. · DOI · Paper page
  20. Wu Q, Huang J, Fan X, et al. Structural mapping of Nav1.7 antagonists. Nat Commun. 2023;14:3224. · DOI
  21. Shiers S, Klein RM, Price TJ. Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated with RNAscope in situ hybridization. Pain. 2020;161(10):2410–24. · DOI · Paper page
  22. Ray P, Torck A, Quigley L, et al. Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research. Pain. 2018;159(7):1325–45. · DOI · Paper page
  23. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41(3):171–4. · DOI · Paper page
  24. Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52(5):767–74. · DOI · Paper page
  25. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121):894–8. · DOI · Paper page
  26. Faber CG, Lauria G, Merkies ISJ, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A. 2012;109(47):19444–9. · DOI · Paper page
  27. Han C, Vasylyev D, Macala LJ, et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry. 2014;85(5):499–505. · DOI
  28. Leipold E, Liebmann L, Korenke GC, et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet. 2013;45(11):1399–404. · DOI · Paper page
  29. Leipold E, Hanson-Kahn A, Frick M, et al. Cold-aggravated pain in humans caused by a hyperactive NaV1.9 channel mutant. Nat Commun. 2015;6:10049. · DOI
  30. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379(6562):257–62. · DOI · Paper page
  31. Hameed S. Na(v)1.7 and Na(v)1.8: role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801. · DOI · Paper page
  32. Han C, Estacion M, Huang J, et al. Human Na(v)1.8: enhanced persistent and ramp currents contribute to distinct firing properties of human DRG neurons. J Neurophysiol. 2015;113(9):3172–85. · DOI
  33. Digre A, Lindskog C. The human protein atlas - Integrated omics for single cell mapping of the human proteome. Protein Sci. 2023;32(2): e4562. · DOI
  34. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 2005;57(4):397–409. · DOI · Paper page
  35. Jones J, Correll DJ, Lechner SM, et al. Selective inhibition of NaV1.8 with VX-548 for acute pain. N Engl J Med. 2023;389(5):393–405. · DOI · Paper page
  36. Clairfeuille T, Cloake A, Infield DT, et al. Structural basis of α-scorpion toxin on NaV channels. Science. 2019;363(6433): eaav8573. · DOI · Paper page
  37. Shen H, Zhou Q, Pan X, et al. Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. Science. 2017;355(6328): eaal4326. · DOI · Paper page
  38. Jasial S, Hu Y, Vogt M, Bajorath J. Activity-relevant similarity values for fingerprints and implications for similarity searching. Chem Inf Sci. 2016;5:591.
  39. Patterson DE, Cramer RD, Ferguson AM, Clark RD, Weinberger LE. Neighborhood behavior: a useful concept for validation of “molecular diversity” descriptors. J Med Chem. 1996;39(16):3049–59. · DOI · Paper page
  40. BIGL package in R version 4.4.1: https://www.nature.com/articles/s41598-017-10868-5.
  41. Moser VC, Ross JF. US EPA/AIHC training video and reference manual for a functional observational batter. Washington, DC: Environmental Protection Agency; 1996.
  42. Moser VC, McCormick JP, Creason JP, MacPhail RC. Comparison of chlordimeform and carbaryl using a functional observational battery. Fund Appl Toxicol. 1988;11:189–206. · DOI · Paper page
  43. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore and hindlimb grip strength of rats and mice. Neurobehav Toxicol. 1979;1:233–6.
  44. Edwards PM, Parker VH. A simple, sensitive and objective method for early assessment of acrylamide neuropathy in rats. Toxicol Appl Pharmacol. 1977;40:589–91. · DOI
  45. Ankier SI. New hot plate tests to quantify anti-nociceptive and narcotic antagonist activities. Eur J Pharmacol. 1974;27:1–4. · DOI
  46. Olsen Y. What is addiction? History, terminology, and core concepts. Med Clin N Amer. 2022;106:1–12. · DOI
  47. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26:13–25. · DOI · Paper page
  48. Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. Anesth Prog. 2012;59:90–102. · DOI · Paper page
  49. El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local Reg Anesth. 2018;11:35–44. · DOI · Paper page
  50. Gilchrist JM, Yang N-D, Jiang V, Moyer BD. Pharmacologic characterization of LTGO-33, a selective small molecule inhibitor of the voltage-gated sodium channel NaV1.8 with a unique mechanism of action. Mol Pharmacol. 2024;105:233–49. · DOI

Cited by

See all 186

Metadata

Authors
Osteen, J. D., Immani, S., Tapley, T. L., Indersmitten, T., Hurst, N. W., Healey, T., Aertgeerts, K., Negulescu, P. A., & Lechner, S. M.
Venue
Pain and Therapy
Published
2025-01-08
Volume
14
Issue
2
Pages
655-674
ISSN
  • 2193-651X (ISSN-L)
  • 2193-8237
OpenAlex
W4406160428
Cited by
186
References
9
FWCI
99.99
Type
journal article
Language
en
Open access
gold
Licence
Funders
Vertex Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. https://app.cochat.ai/papers/10.1007/s40122-024-00697-0
The paper
Osteen, J. D., Immani, S., Tapley, T. L., Indersmitten, T., Hurst, N. W., Healey, T., Aertgeerts, K., Negulescu, P. A., & Lechner, S. M. (2025). Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain and Therapy. https://doi.org/10.1007/s40122-024-00697-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.